Season 1 Episode 4.3 - Using Third-Party Tools with AI Inside

The way life sciences companies have commercialised products for years is being challenged from every direction. Changing customer expectations, growing market complexity, new technologies, and evolving healthcare ecosystems are all raising the same question:Is improving the current model enough, or is it time to rethink it altogether?In Season 2, Episode 5.2 of The Improzone, Jane Urban continues her conversation with Indraneel Mukherjee, Partner at Guidehouse, to explore what meaningful commercial transformation actually looks like.From reimagining commercial models and modernising workflows to the role of governance, organisational change, and AI-enabled execution, this episode examines why transformation isn't about adding another tool or another process. It's about redesigning how organisations make decisions, operate at scale, and prepare for what's next.Because lasting transformation doesn't happen by simply doing the same things faster. It begins by questioning what should change, what should stay, and having the confidence to build a better way forward.#LifeSciences #CommercialStrategy #CommercialTransformation #Pharma #DigitalTransformation #AI #Improzo

AI is changing the way life sciences organisations think about technology, talent, and transformation. But as the pace of innovation accelerates, one question is becoming harder to ignore:What should companies build themselves, what should they partner for, and what does the future workforce need to succeed in an AI-first world?In Season 2, Episode 5.1 of The Improzone, Jane Urban is joined by Indraneel Mukherjee, Partner at Guidehouse, for a thought-provoking conversation on how life sciences organisations can navigate the next wave of AI transformation.From the build vs. buy debate and AI talent strategies to workforce readiness, organisational change, and the importance of combining strategic thinking with execution, this episode explores the decisions that will shape the future of commercial organisations.Because succeeding with AI isn't just about adopting new technology. It's about building the right capabilities, making better decisions, and creating organisations that are ready for what's next.How do you see the balance between building AI capabilities in-house and partnering with experts evolving over the next few years? #ImprozonePodcast #LifeSciences #ArtificialIntelligence #CommercialStrategy #DigitalTransformation #Pharma #AITransformation #Improzo

Season 2 Miniseries Episode 4.3 is officially live.New Improzone Podcast Episode In this episode, Jane Urban sits down with Jason Harlander (Executive Director, Technology Management, Improzo) to explore what the future of CRM in life sciences could look like and why the next evolution of CRM is less about technology and more about creating value for the people who use it every day.Key takeaways:Why CRM must evolve from a compliance tool into a system that genuinely supports field teamsHow poor data quality and low adoption create a cycle that limits the value of both CRM and AIWhere AI is already delivering impact today, from voice-enabled call reporting to next best actionsWhy earning trust through small, practical AI wins matters more than ambitious "slideware" promisesThe three priorities leaders should focus on: strong data foundations, accurate field models, and targeted automationWhy CRM decisions should be treated as a commercial strategy, not just an IT implementationA thought-provoking conversation on putting the "relationship" back into customer relationship management and building systems that work better for both people and business outcomes.#ImprozonePodcast #CRM #LifeSciences #ArtificialIntelligence #PharmaTech #DigitalTransformation #CommercialOperations #CustomerExperience #Improzo

Season 2 Miniseries Episode 4.2 is officially live.New Improzone Podcast EpisodeIn this episode, Jane Urban sits down with Jason Harlander (Executive Director, Technology Management, Improzo) to unpack the present-day realities of CRM transformation, where life sciences, data, and technology intersect, and where teams are now being forced to make some of their most critical platform decisions.Key takeaways:- Why CRM decisions today are no longer just about features, but about entire enterprise ecosystems- The real trade-offs between Veeva Vault CRM and Salesforce Life Sciences Cloud in pharma environments- How platform depth across clinical, regulatory, and commercial systems is reshaping migration complexity- The hidden cost layers from integrations to change management, that often define success or failure- How AI-driven narratives from both platforms are influencing (but not yet proving) real-world outcomes- Why early-stage biotech companies are increasingly locking into ecosystems like Veeva Basics from day oneA grounded, real-world conversation on what’s actually happening inside CRM decision rooms today, the pressure, the complexity, and the trade-offs that don’t always show up in presentations.#improzonepodcast #crm #lifesciences #digitaltransformation #customerexperience #pharmatech #aiinhealthcare #improzo

Season 2 Episode 4.1 is officially live.New Improzone Podcast EpisodeIn this episode, Jane Urban sits down with Jason Harlander (Executive Director, Technology Management, Improzo) to explore the origins of CRM in life sciences and how early decisions continue to shape the industry today.Key takeaways:* How Salesforce started as a SaaS disruptor and built the foundation for modern CRM* Why Veeva’s vertical-first approach transformed pharma CRM adoption* The role of force.com in accelerating innovation without building from scratch* How early strategic decisions helped Veeva capture massive market share* What the Veeva Salesforce split means for the industry todayA grounded conversation on where CRM really came from and why understanding its history is key to making better decisions moving forward.

New Improzone Podcast EpisodeJane Urban sits down with Navdeep Singh (AWS Customer Success Leader) to explore Perception vs. Perspective: Rethinking AI Adoption in Biopharma, a conversation that goes beyond the hype to examine how AI is actually being adopted across life sciences organizations today.Key takeaways:• The gap between how AI is perceived and how it performs in real-world settings• Why adoption challenges are often operational, not technical• The importance of context, governance, and decision ownership in AI systems• Moving beyond pilots toward execution-focused AI strategies• Why human judgment continues to play a critical role alongside AIA grounded, practical conversation on what it really takes to make AI work in biopharma not just in theory, but in execution.#ImprozonePodcast #AIForLifeSciences #Biopharma #AIAdoption #AgenticAI #ImprozoThoughtLeadership

New Improzone Podcast EpisodeJane Urban sits down with Stephen Gatchell (Ortecha) to explore how MDM and AI are evolving together — and why the “golden record” mindset no longer works at scale.Key takeaways:• MDM is shifting from rigid systems of truth to context-driven data philosophies• AI-enabled documentation, observability, and metadata enrichment are changing how data is mastered• Small language models and modular agents outperform one-size-fits-all AI• The real power is human + AI, not automation alone• Entry-level work is changing — but critical thinking and communication matter more than everA practical, honest conversation about what’s actually working — and what’s next.#ImprozonePodcast #AIForLifeSciences #DataStrategy #MDM #AgenticAI #ImprozoThoughtLeadership

Most biotech companies are stuck in "pilot purgatory" with Generative AI. But moving from a fun experiment to a scalable, enterprise-grade solution requires more than just a software license, it demands a fundamental shift in how IT partners with Legal, QA, and Regulatory teams.In the Season 2 premiere of The Improzone, host Jane Urban sits down with Andrew Schwartz (Head of Global IT, KalVista Pharmaceuticals) to break down the roadmap for scaling AI across the enterprise.In this episode, we cover:Shadow IT vs. Enterprise Strategy: Why moving off personal ChatGPT accounts is the first step to security.The "Human-in-the-Loop": How to deploy Agentic AI that assists rather than replaces.Cross-Functional Governance: How to get Legal and QA to say "Yes" to innovation.If you are leading digital transformation in life sciences, this is your blueprint for 2026.#GenerativeAI #LifeSciences #PharmaAI #BiotechInnovation #EnterpriseAI #DigitalTransformation #KalVista #TheImprozone #AIgovernance #Improzo

We are LIVE with the finale of our mini-series! In Episode 4.4 - The AI Adoption Arc, we shift the focus outward to exploring Externally Facing AI Tools.While internal efficiencies are critical, the true competitive advantage in Life Sciences lies in how AI reshapes your customer touchpoints. From personalized HCP engagement to responsive patient support, we unpack how to deploy AI that builds trust rather than just cutting costs.Don’t leave the most visible part of your business in the analog age.#Improzo #LifeSciences #AIAdoption #PharmaTech #CustomerExperience #GenerativeAI #DigitalTransformation

In the latest episode of The Improzone Mini-Series 4.3, we explore the critical shift from legal compliance to technical verification. Key Insight: Treat your third-party AI like an "over-eager intern"—talented, capable, but lacking the judgment to represent your brand without supervision.In this episode, we unpack: - The Limits of Questionnaires: Why paper surveys fail to catch GenAI hallucinations. - Brand vs. Security: Why a secure bot can still be toxic. - Continuous Validation: Why a one-time pen test is already obsolete. Join Jane Urban and Nathan Trueblood for a masterclass in AI procurement safety.#ArtificialIntelligence #PharmaTech #DigitalHealth #RiskManagement #AIEthics #VendorManagement #TechLeadership #EnkryptAI #Improzo